BioAffinity Technologies recently announced that CFO Michael Dougherty has resigned, and J. Michael Edwards was appointed interim CFO.

Dougherty is resigning to take on a CFO position in the Pacific Northwest energy industry. He will continue to serve in his role until September 15 and will assist in the transition. BioAffinity Technologies appointed him as CFO in May 2023.

“I am grateful for the opportunity to work for bioAffinity Technologies and support its mission for the early detection of lung cancer. I’m proud of our accomplishments and leave with mixed emotions for this unexpected opportunity in the Pacific Northwest closer to home and family,” Dougherty said. “I have every confidence in the team we built and the financial planning and processes we implemented. I know this team will ensure the ongoing success of the Finance Department.”

Edwards served as BioAffinity’s consulting CFO from 2014 to 2023 and oversaw the company’s public offering in 2022. He will serve as interim CFO until the company appoints a permanent replacement.

“We expect a seamless transition given the strong team and financial processes that Mike Dougherty has put in place and Michael Edwards’ extensive experience as bioAffinity’s previous CFO,” President and CEO Maria Zannes said in a news release. “During his tenure, Mike Dougherty played an important role in the acquisition of Precision Pathology Laboratory Services and the growth in adoption of CyPath Lung, our noninvasive test for lung cancer. Mike has made significant contributions to bioAffinity’s success and is leaving us in good hands. We wish him the very best in his future endeavors.”

Edwards has more than 25 years of experience in corporate finance and accounting. He previously served as CFO of CytoBioscience and OncoVista Innovative Therapies.

BioAffinity Technologies has initiated a search for a permanent CFO.